NCT04246944 Induced Membrane Properties in Children and Adults
| NCT ID | NCT04246944 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Bone Loss |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2019-05-23 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2019-05-23 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Bone reconstruction in critical sized defect (CSD) remains a real challenge in orthopedic surgery in children and adults. The Masquelet technique is an innovative therapeutic technique, which offers a bone reconstruction in two steps, by the formation of an induced membrane (IM) around a polymethylmethacrylate (PMMA) spacer placed into the bone defect. After, PMMA removal, the cavity is filled with corticocancellous graft allowing bone healing. Up to date, all angiogenesis and osteogenic properties of IM remain unknown. The purpose of this study is to characterize angiogenesis and osteogenic properties of IM in children and adults.
Eligibility Criteria
Inclusion Criteria: * All patients treated at CHU Amiens-Picardie for bone critical sized defect treated using the induced membrane reconstruction technique. * patients from 9 months to 60 years old Exclusion Criteria: * Patients managed by another reconstruction technique for critical sized defect * Patients under guardianship, curators or deprived of liberty. * Pregnant and nursing women. * Patients who refused to participate in the study and to sign informed consent.
Contact & Investigator
Céline Klein, MD
PRINCIPAL INVESTIGATOR
CHU Amiens
Frequently Asked Questions
Who can join the NCT04246944 clinical trial?
This trial is open to participants of all sexes, aged 9 Months or older, up to 60 Years, studying Bone Loss. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04246944 currently recruiting?
Yes, NCT04246944 is actively recruiting participants. Contact the research team at klein.celine@chu-amiens.fr for enrollment information.
Where is the NCT04246944 trial being conducted?
This trial is being conducted at Amiens, France.
Who is sponsoring the NCT04246944 clinical trial?
NCT04246944 is sponsored by Centre Hospitalier Universitaire, Amiens. The principal investigator is Céline Klein, MD at CHU Amiens. The trial plans to enroll 50 participants.